University of Texas M. D. Anderson Cancer Center Apr 21 2026 Direct injection of a low dose of the immune checkpoint inhibitor nivolumab into precancerous oral lesions significantly reduced lesion size and risk of cancer progression, sparing most patients from surgery. This new research from The University of Texas MD Anderson Cancer Center suggests a novel approach to oral cancer prevention through immune interception. Results from the first-in-human Phase I trial were presented today at the